Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Pamplona – page 27

753 clinical trials in Pamplona, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pamplona at a glance
753
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

753 trials in Pamplona

Open in trial search

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ZAMPILIMAB
  • Sponsor:Chiesi Farmaceutici S.p.A.

A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Vall D Hebron Institute Of Oncology

Chronic kidney disease

Not yet recruiting

A study to evaluate the effect of survodutide on protein levels in the urine for patients with chronic kidney disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Universitair Medisch Centrum Groningen

Graft versus host disease

Not yet recruiting

Study of Mesenchymal Stromal Cells expressing CXCR4 and IL-10 for patients with acute Graft Versus Host Disease who do not respond to steroids or ruxolitinib

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:ALLOGENEIC ADIPOCYTE-DERIVED MESENCHYMAL STROMAL CELLS TRANSDUCED WITH A LENTIVIRAL PROVIRUS VECTOR CONTAINING THE HUMAN CXCR4 AND IL-10 GENES
  • Sponsor:Fundacion Instituto De Investigacion Sanitaria De Navarra

Non-small cell lung cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merus B.V.

Embolism

Not yet recruiting

A study to compare REGN7508 and acetylsalicylic acid for preventing blood clots in adults undergoing elective total knee replacement.

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Regeneron Pharmaceuticals Inc.

Acute lymphocytic leukaemia+1

Not yet recruiting

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Amgen Inc.

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:AstraZeneca AB

Hepatocellular carcinoma

Not yet recruiting

A study to evaluate the safety and effectiveness of AZD9793 in adults with advanced or metastatic liver cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

A study to evaluate the safety and effectiveness of PTT-4256 and nivolumab in patients with solid tumors.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Pathios Therapeutics Limited

Glioblastoma

Not yet recruiting

Phase 3 Randomized Study of Niraparib Tosilate Monohydrate vs. Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Neurotrials LLC

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Pamplona

What the registry says about research in the country

01 Oncology Research

Innovative trials exploring treatments for various cancers, including metastatic colorectal cancer, bladder cancer, and prostate cancer. Studies focus on combination therapies and novel treatment approaches.

  • Colorectal Cancer Treatment Studies
  • Prostate Cancer Therapies
  • Blood Cancer Research

Multiple trials evaluating immunotherapies and targeted treatments for improving patient outcomes.

02 Immunology and Inflammation

Research focused on treating autoimmune conditions and inflammatory disorders, including studies on cutaneous lupus erythematosus and atopic dermatitis.

  • Lupus Treatment Studies
  • Dermatological Conditions
  • Immune System Disorders

Evaluating new therapeutic approaches for chronic inflammatory conditions.

03 Respiratory Medicine

Clinical investigations targeting respiratory conditions, including studies on COPD and respiratory viral infections. Research focuses on improving treatment outcomes.

  • COPD Management
  • Respiratory Virus Prevention
  • Nasal Polyps Treatment

Development of innovative therapies for respiratory diseases and infections.

04 Metabolic Disorders

Studies addressing obesity, diabetes, and related metabolic conditions. Research focuses on weight management and blood sugar control.

  • Type 2 Diabetes Treatment
  • Weight Management Therapies
  • Metabolic Disease Research

Investigating new approaches for metabolic disorder management.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.